Update on Hepatits B Therapy
نویسندگان
چکیده
منابع مشابه
Diffuse large B-cell lymphoma: update on therapy and prognosis
The introduction of rituximab in combination with chemotherapy has substantially changed the outcome of patients with diffuse large B-cell lymphoma. This update will discuss the factors that improved our predictive capacity in these lymphomas and the results obtained by large clinical trials in first-line and salvage therapy. As far as first-line therapy is concerned, mature data are available ...
متن کاملUpdate on Anti-EGFR Therapy
1Department of Clinical Oncology, Queen Mary Hospital, Pokfulam, Hong Kong 2Department of Gynecologic Oncology, University Hospital Erlangen, 91023 Erlangen, Germany 3Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong 4Department of Medical Oncology, Chiang Mai University, Chiang Mai 50200, Thailand 5Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard ...
متن کاملB-cell-targeted therapy for systemic lupus erythematosus: an update.
Systemic lupus erythematosus (SLE) is a classic autoimmune disease characterized by a myriad of immune system aberrations, most likely resulting from pathogenic autoantibody production, immune complex deposition, and subsequent end-organ damage. B cells play a key role in the pathogenesis; therefore, B-cell-targeted therapies, including B-cell depletion and blockage of B-cell survival factors s...
متن کاملUpdate on occult hepatitis B virus infection
The event of mutations in the surface antigen gene of hepatitis B virus (HBV) results in undetectable hepatitis B surface antigen with positive/negative anti-hepatitis B core (anti-HBc) antibody status in serum and this phenomenon is named occult hepatitis B infection (OBI). The presence of anti-HBc antibody in serum is an important key for OBI tracking, although about 20% of OBI cases are nega...
متن کاملB-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence
Systemic sclerosis (SSc) is a systemic rheumatic disease with poor prognosis since therapeutic options are limited. Recent evidence from animal models suggests that B-cells may be actively involved in the fibrotic process. B-cells from tight skin mice, an animal model of scleroderma, display a "hyperresponsive" phenotype; treatment with rituximab (RTX) significantly attenuates skin fibrosis in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Infectious Diseases
سال: 2010
ISSN: 1201-9712
DOI: 10.1016/j.ijid.2010.02.1515